Combination Therapy for Ocular Surface Disease: A Framework for Modern Practice

We face a persistent and difficult question when treating dry eye patients: Which patients need combination therapy? My answer is almost all of them. Most dry eye patients have both an evaporative component and an aqueous-deficient component. Treating one in isolation and waiting to see what happens is not exactly bad medicine, but it is inefficient and delays the relief patients could be experiencing. In a busy clinic like mine, neither the patient nor staff wants to wait any longer than necessary for relief and spend any more time in the exam chair than necessary. 

WHY ALMOST EVERYONE HAS MIXED DISEASE 

Digital device use is the obvious culprit. When patients stare at a screen, both blink frequency and quality drop. Each complete blink pumps meibum from the meibomian glands and refreshes the tear film’s lipid layer. When blinking decreases in frequency and depth, meibomian gland function suffers. We are seeing this across all age groups and demographics. 

Layer in systemic factors like dehydration, sleep disruption, stress, systemic medications that reduce aqueous production, and you have a meaningful aqueous-deficiency component overlapping with the evaporative one. 

Overlapping etiology is the rule, not the exception. Patients who present with purely aqueous-deficient disease (eg, severe autoimmune cases such as Sjögren’s syndrome, where the glands are intact) are the ones I do not automatically put on combination therapy. But for the broad majority, if I’m doing a thorough exam and looking at both the front of the eye and the gland function, I find evidence of both causes. 

This is why I do not approach dry eye as a stepladder where I start with one drop, wait 3 months, and add another if it fails. That model protects against overtreatment but underserves the patient who is symptomatic, frustrated, and, in many cases, already on their fourth or fifth eye doctor. Starting concurrent treatment on day 1 and addressing inflammation and meibomian glands simultaneously gives patients the fastest possible path to relief. 

WHAT MY COMBINATION REGIMENS ACTUALLY LOOK LIKE 

The core of most regimens is an immunomodulator—Restasis, XIIDRA, or VEVYE (see Dr. Dunbar’s article for additional details)— combined with thermal therapy for the meibomian glands. I am a strong proponent of heat for patients who do not have ocular rosacea. Heat is effective, accessible, and, when done right, leads to patient compliance. 

The compliance piece is where device selection matters. The Bruder reusable heat mask is best-in-class for therapeutic effect: patients microwave it, wear it for 8 to 10 minutes, and the deep, moist heat opens the glands in a way that dry heat cannot replicate. Many patients do well with it. 

However, some patients, especially those with mobility limitations or who simply are not going to get up and go to the microwave every night, will not use it consistently. Inconsistent heat therapy is ineffective because meibomian glands need regular clearance to remain functional. For those patients, I recommend the Eyedration Air-Activated Mask by Bruder (full disclosure: I invented it), a single-use mask that heats itself via air activation. Leave it on the nightstand, open it when needed, wear it for 15 minutes, then recycle it. The barrier to use is lower, and consistent use beats irregular use. 

Beyond drops and heat, I incorporate supplementation for most patients. I have been leaning more heavily on the Blink NutriTears (Bausch + Lomb) supplement and have also developed my own product, Dry Eye Drink, a powder drink mix loaded with anti-inflammatories that patients take before bed. Omega supplementation remains evidence-based, and I often suggest DE3 (PRN Neutraceuticals) and Hydro Eyes (ScienceBased Health). 

Real-world barriers to supplemental or nutraceutical adherence include large pills, multiple doses, and out-of-pocket costs. In my Louisiana practice, where a meaningful percentage of patients struggle financially, the decision to recommend expensive supplements that insurance does not cover requires judgment about what a patient will actually use. 

HYPOCHLOROUS ACID AND INCOMPLETE LID SEAL: TWO OFTEN-MISSED COMPONENTS

A surprising number of patients have lid margin debris, specifically a foamy or bubbly accumulation resulting from bacterial byproducts at the lid margin. Hypochlorous acid sprays, including the Bruder hypochlorous acid spray, effectively address this and are well tolerated. I have had good results incorporating hypochlorous acid into combination regimens, particularly in patients who are not responding as expected to other components of their therapy. 

The other condition I find consistently underdiagnosed is incomplete lid seal, sometimes called nocturnal lagophthalmos. If lids do not close completely during sleep, the ocular surface desiccates overnight. 

Patients often are unaware that they fail to completely close their lids at night. They present with morning symptoms, sometimes with findings that look worse than their daytime tear production would predict. Simple bedside tests can check for incomplete lid closure, and the management with a lubricating ointment at night is straightforward. I often suggest Hylo Night (Optase) to patients with nocturnal lagophthalmos. 

When this condition is missed and treated as standard dry eye, patients make limited progress. When it is identified and the overnight protection is added, results often improve quickly. 

DEMODEX: ON EVERY EXAM 

I check for Demodex during every dry eye examination, regardless of the patient’s age. Collarettes, the cylindrical deposits at the base of lash follicles, are pathognomonic for Demodex infestation. They are easy to see if you look for them, and easy to overlook if you do not. 

I regularly prescribe XDEMVY (oclacitinib ophthalmic solution 0.1%, Tarsus Pharmaceuticals); it is the only FDA-approved prescription eye drop to kill Demodex mites. Insurance coverage is usually not an issue for most patients who need it. When coverage is unavailable or the patient cannot access it, I reach for mechanically acting alternatives: the Avenova hypochlorous acid wipe or the Bruder tea tree oil wipes, both of which I use frequently. 

The point is not just to treat what is present. It is to look for it on every exam. Demodex blepharitis contributes to lid margin disease and, in turn, to MGD. It is part of the same constellation of pathology. If you are treating dry eye without checking for Demodex, you may be managing only a symptom. 

LIFESTYLE MODIFICATIONS: UNDERUSED AND UNDERESTIMATED 

I have leaned heavily into lifestyle counseling over the past few years, and the results have surprised me. The connection between systemic health and ocular surface health is not abstract. Sleep disruption increases systemic inflammation. Dehydration reduces aqueous production. Stress hormones affect the lacrimal system. A diet high in processed food and refined sugars promotes a pro-inflammatory environment. None of this is specific to the eye, which is exactly the point. 

Even in patient populations with lower health literacy, this framing resonates more than practitioners expect. Many of my dry eye patients also have diabetes, autoimmune disease, or hypertension. They have already been told by other physicians that lifestyle factors affect their systemic conditions. The connection to eye health fits a framework they already understand. I recommend sleep hygiene, increased water intake, reduced soda consumption, omega fatty acid intake, and stress reduction through exercise or meditation. These are not substitutes for pharmaceutical therapy. They are part of a genuine combination approach. 

FOLLOW-UP ALGORITHMS 

Follow-up intervals depend on what I have prescribed. For acute interventions, I want to see the patient in 2 to 4 weeks. For simpler regimens anchored in artificial tears and home heat, I can often wait 4 to 6 weeks before reassessing. Cyclosporine use requires patience; full effect can take 3 to 4 months, and I tell patients this explicitly. Without that expectation, they may assume the drug is not working and discontinue early. 

I am apt to switch treatment tactics if patient-reported intolerance or objective lack of improvement is observed during an appropriate trial period. If a patient reports that a drop burns consistently, causes prolonged blurred vision, or gives them a persistent bad taste from drainage, I make a change. Over time, I have become more willing to encourage patients to push through a few weeks to see if side effects resolve. The clinical lesson I have observed is that sticking with a drug long enough to assess it properly yields better outcomes than switching at the first sign of a problem. 

WHAT SUCCESS LOOKS LIKE 

I define dry eye success not as symptom elimination but as symptom stability. Fewer bad days. Less day-to-day variability. More predictable vision throughout the day. Better end-of-day comfort. Improved contact lens tolerance for patients who wear lenses. Improved tear stability and gland function on objective testing over time. 

Patients who come to me after seeing multiple providers, which is common, often have had success redefined for them in narrow terms. They have been told nothing more can be done, or that dry eye is just something they must manage. In my practice, the combination approach— addressing inflammation, meibomian gland function, lid margin health, Demodex (if present), lifestyle factors, and sleep—reframes what is possible. 

Not every patient achieves dramatic improvement. But when you treat the whole picture from day 1, rather than sequentially and partially, the aggregate outcomes are meaningfully better.